Recent advances in imaging and understanding interstitial cystitis

Pradeep Tyagi, Chan-Hong Moon, Joseph Janicki, Jonathan Kaufman, Michael Chancellor, Naoki Yoshimura, Christopher Chermansky, Pradeep Tyagi, Chan-Hong Moon, Joseph Janicki, Jonathan Kaufman, Michael Chancellor, Naoki Yoshimura, Christopher Chermansky

Abstract

Interstitial cystitis/bladder pain syndrome (IC/BPS) is a debilitating condition associated with intense pelvic pain and bladder storage symptoms. Since diagnosis is difficult, prevalence estimates vary with the methodology used. There is also a lack of proven imaging tools and biomarkers to assist in differentiation of IC/BPS from other urinary disorders (overactive bladder, vulvodynia, endometriosis, and prostatitis). Current uncertainty regarding the etiology and pathology of IC/BPS ultimately impacts its timely and successful treatment, as well as hampers future drug development. This review will cover recent developments in imaging methods, such as magnetic resonance imaging, that advance the understanding of IC/BPS and guide drug development.

Keywords: Interstitial cystitis; MRI; bladder wall; fibrosis; imaging; radiation.

Conflict of interest statement

Competing interests: Joseph Janicki is an employee of Lipella Pharmaceuticals, whereas Jonathan Kaufman and Michael Chancellor are inventors of novel contrast mixture. Pradeep Tyagi, Chan-Hong Moon, Naoki Yoshimura and Christopher Chermansky declare that they have no competing interests.No competing interests were disclosed.No competing interests were disclosed.

Figures

Figure 1.. Magnetic resonance imaging (MRI) is…
Figure 1.. Magnetic resonance imaging (MRI) is superior to computed tomography (CT) in bladder wall segmentation.
Contrast-enhanced T 1-weighted MRI (PanelC) is superior to CT (PanelA) and unenhanced T 1-weighted MRI (PanelB) for resolving the thickened bladder wall of the same female ulcerative interstitial cystitis/bladder pain syndrome (IC/BPS) patient as indicated by a red line drawn across the bladder wall. Representative T 1-weighted fast low angle shot (FLASH) images acquired at the flip angle of 14° in orthogonal orientation before (PanelB) and after novel contrast mixture (NCM) instillation (PanelC) demonstrate that NCM-enhanced MRI can non-invasively segment the bladder wall into a middle layer of bright signal intensity sandwiched between inner and outer layers of lower signal intensity. Fibrotic changes reported in the pathological results of the biopsy from the IC/BPS patient are visible as the bright middle layer from the diffusion of gadobutrol from NCM instilled in the lumen (hypointense circular region in PanelC). Fast acquisition of a single slice (5 mm thickness) over a single breath hold of approximately 17 seconds with imaging parameters of repetition time (TR)/echo time (TE) of 5.5/2 milliseconds, field of view of 180×180 mm 2, matrix of 256×256 and 10 averaging achieved in-plane resolution of 0.35 mm (after 2x interpolation) with minimal influence of motion and chemical shift artifacts (PanelB andC). Akin to CT (PanelA), T 1-weighted MRI (PanelB) with similar imaging parameters as in PanelC could not resolve the bladder wall from the lumen in the absence of NCM owing to the relatively long intrinsic T 1 relaxation time of >1 second for the bladder wall and of urine in the lumen. Although the bladder wall is demarcated clearly in pre-contrast T 2-weighted image (PanelD andE) acquired at the TR/TE of 6.9/3.1 milliseconds, there is underestimation of bladder wall thickness, especially of the inner layer from 3.62 mm in panel C to 1.21 mm in PanelE. Instillation of gadobutrol in the absence of ferumoxytol enhances the T 1 contrast of urine as well as the bladder wall, which precludes it from affording improved image contrast. This figure is an original image taken in our clinic for this publication.
Figure 2.. Near infra-red imaging.
Figure 2.. Near infra-red imaging.
Representative images for the rat pelvic area in visible light and in near infra-red (NIR) light after instillation of liposomes containing a trace amount of NIR dye. Deep tissue imaging of the bladder wall is possible, as light emitted from the bladder lumen in the NIR band encounters low background auto-fluorescence and minimal absorption by tissue components. This figure is an original image taken in our clinic for this publication.
Figure 3.. Contrast-enhanced magnetic resonance imaging (MRI)…
Figure 3.. Contrast-enhanced magnetic resonance imaging (MRI) relies on the diffusion of gadolinium into the bladder wall.
Novel contrast mixture-enhanced MRI relies on the differences in the contrast mechanisms and molecular weight of two US Food and Drug Administration-approved agents (gadobutrol diluted 1:250 and ferumoxytol diluted 1:104) for increasing the contrast resolution of the bladder wall (PanelA). Gadobutrol, a transparent liquid, is a gadolinium-based contrast agent (GBCA) with a molecular weight of 604.71 Da that reaches the extracellular space in the lamina propria to shorten T 1 (positive contrast) or produce higher signal intensity (PanelA andB). Meanwhile, the large molecular weight of 750 kDa for ferumoxytol (vial with brown-colored liquid) restricts its bladder wall diffusion, and it produces a localized increase in proton dephasing, which decreases the signal intensity (negative contrast) in T 1-weighted images. Instillation of novel contrast mixture 50 mL can non-invasively segment the inner layer (urothelium) and the outer layer of adventitia (dark signal) from the bright signal in the middle layer composed of the lamina propria and detrusor smooth muscle (PanelC). Bladder wall histology in PanelC is shown for illustration and does not represent the pathological characterization of the interstitial cystitis/bladder pain syndrome (IC/BPS) patient shown in PanelB. This figure is an original image taken in our clinic for this publication.
Figure 4.. Quantitative measurement of gadolinium diffusion.
Figure 4.. Quantitative measurement of gadolinium diffusion.
T 1-weighted fast low angle shot (FLASH) images with constant repetition time (TR) of 5.5 milliseconds (ms) at flip angle (FA) of 6° (PanelA,C, andE) and 14° (PanelB,D, andE) demonstrate that gadobutrol-mediated signal enhancement (visible in the right tube containing gadobutrol 4 mM alone) is suppressed by the presence of ferumoxytol (5 mM) in the novel contrast mixture (NCM) tube, as the gadobutrol concentration of 4 mM is the same in both tubes (PanelA andB). T 1-weighted FLASH images demonstrates that greater separation of gadobutrol into the bladder wall away from the NCM instilled in the bladder lumen occurs in ulcerative IC/BPS patients (PanelE andF) than in non-ulcerative interstitial cystitis/bladder pain syndrome (IC/BPS) patient (PanelC andD), which is evident from the dramatic increase in signal intensity in PanelF relative to PanelD at FA of 14°. Catheter used for instillation is shown byC in panelC–H. Constant TR of 5.5 ms at different FAs achieves the stable steady-state conditions necessary for the differences in signal intensity of the same slice to become a function of T 1 relaxation time as indicated by the color panel in PanelH. Greater shortening of T 1 relaxation time (blue color) in ulcerative IC/BPS patients is consistent with higher diffusion of gadobutrol into the expanded extracellular matrix of the thickened bladder wall of IC/BPS patients. This figure is an original image taken in our clinic for this publication.

References

    1. Wennevik GE, Meijlink JM, Hanno P, et al. : The Role of Glomerulations in Bladder Pain Syndrome: A Review. J Urol. 2016;195(1):19–25. 10.1016/j.juro.2015.06.112
    1. Doggweiler R, Whitmore KE, Meijlink JM, et al. : A standard for terminology in chronic pelvic pain syndromes: A report from the chronic pelvic pain working group of the international continence society. Neurourol Urodyn. 2017;36(4):984–1008. 10.1002/nau.23072
    1. Mullins C, Bavendam T, Kirkali Z, et al. : Novel research approaches for interstitial cystitis/bladder pain syndrome: thinking beyond the bladder. Transl Androl Urol. 2015;4(5):524–33. 10.3978/j.issn.2223-4683.2015.08.01
    1. Suskind AM, Berry SH, Ewing BA, et al. : The prevalence and overlap of interstitial cystitis/bladder pain syndrome and chronic prostatitis/chronic pelvic pain syndrome in men: results of the RAND Interstitial Cystitis Epidemiology male study. J Urol. 2013;189(1):141–5. 10.1016/j.juro.2012.08.088
    1. Tung A, Hepp Z, Bansal A, et al. : Characterizing Health Care Utilization, Direct Costs, and Comorbidities Associated with Interstitial Cystitis: A Retrospective Claims Analysis. J Manag Care Spec Pharm. 2017;23(4):474–82. 10.18553/jmcp.2017.23.4.474

    2. F1000 Recommendation

    1. Hanno PM, Erickson D, Moldwin R, et al. : Diagnosis and treatment of interstitial cystitis/bladder pain syndrome: AUA guideline amendment. J Urol. 2015;193(5):1545–53. 10.1016/j.juro.2015.01.086
    1. Walker SJ, Zambon J, Andersson KE, et al. : Bladder Capacity is a Biomarker for a Bladder Centric versus Systemic Manifestation in Interstitial Cystitis/Bladder Pain Syndrome. J Urol. 2017;198(2):369–75. 10.1016/j.juro.2017.02.022
    1. Akiyama Y, Morikawa T, Maeda D, et al. : Increased CXCR3 Expression of Infiltrating Plasma Cells in Hunner Type Interstitial Cystitis. Sci Rep. 2016;6: 28652. 10.1038/srep28652
    1. Maeda D, Akiyama Y, Morikawa T, et al. : Hunner-Type (Classic) Interstitial Cystitis: A Distinct Inflammatory Disorder Characterized by Pancystitis, with Frequent Expansion of Clonal B-Cells and Epithelial Denudation. PLoS One. 2015;10(11):e0143316. 10.1371/journal.pone.0143316
    1. Ackerman AL, Lee UJ, Jellison FC, et al. : MRI suggests increased tonicity of the levator ani in women with interstitial cystitis/bladder pain syndrome. Int Urogynecol J. 2016;27(1):77–83. 10.1007/s00192-015-2794-6
    1. Kairys AE, Schmidt-Wilcke T, Puiu T, et al. : Increased brain gray matter in the primary somatosensory cortex is associated with increased pain and mood disturbance in patients with interstitial cystitis/painful bladder syndrome. J Urol. 2015;193(1):131–7. 10.1016/j.juro.2014.08.042
    1. Kilpatrick LA, Kutch JJ, Tillisch K, et al. : Alterations in resting state oscillations and connectivity in sensory and motor networks in women with interstitial cystitis/painful bladder syndrome. J Urol. 2014;192(3):947–55. 10.1016/j.juro.2014.03.093

    2. F1000 Recommendation

    1. Lynes WL, Flynn SD, Shortliffe LD, et al. : The histology of interstitial cystitis. Am J Surg Pathol. 1990;14(10):969–76. 10.1097/00000478-199010000-00011
    1. Logadottir Y, Delbro D, Fall M, et al. : Cytokine expression in patients with bladder pain syndrome/interstitial cystitis ESSIC type 3C. J Urol. 2014;192(5):1564–8. 10.1016/j.juro.2014.04.099
    1. Kastrup J, Hald T, Larsen S, et al. : Histamine content and mast cell count of detrusor muscle in patients with interstitial cystitis and other types of chronic cystitis. Br J Urol. 1983;55(5):495–500. 10.1111/j.1464-410X.1983.tb03356.x
    1. Yoshimura N, Seki S, Chancellor MB, et al. : Targeting afferent hyperexcitability for therapy of the painful bladder syndrome. Urology. 2002;59(5 Suppl 1):61–7. 10.1016/S0090-4295(01)01639-9
    1. Pang X, Marchand J, Sant GR, et al. : Increased number of substance P positive nerve fibres in interstitial cystitis. Br J Urol. 1995;75(6):744–50. 10.1111/j.1464-410X.1995.tb07384.x
    1. Erickson DR, Belchis DA, Dabbs DJ: Inflammatory cell types and clinical features of interstitial cystitis. J Urol. 1997;158(3 Pt 1):790–3. 10.1016/S0022-5347(01)64317-9
    1. Esteban M, Adot JM, Arlandis S, et al. : Recommendations for the Diagnosis and Management of Bladder Pain Syndrome. Spanish Urological Association Consensus Document. Actas Urol Esp. 2015;39(8):465–72. 10.1016/j.acuro.2015.01.006
    1. Gamper M, Regauer S, Welter J, et al. : Are mast cells still good biomarkers for bladder pain syndrome/interstitial cystitis? J Urol. 2015;193(6):1994–2000. 10.1016/j.juro.2015.01.036
    1. Theoharides TC, Kempuraj D, Sant GR: Mast cell involvement in interstitial cystitis: a review of human and experimental evidence. Urology. 2001;57(6 Suppl 1):47–55. 10.1016/S0090-4295(01)01129-3
    1. Slobodov G, Feloney M, Gran C, et al. : Abnormal expression of molecular markers for bladder impermeability and differentiation in the urothelium of patients with interstitial cystitis. J Urol. 2004;171(4):1554–8. 10.1097/01.ju.0000118938.09119.a5
    1. Eldrup J, Thorup J, Nielsen SL, et al. : Permeability and ultrastructure of human bladder epithelium. Br J Urol. 1983;55(5):488–92. 10.1111/j.1464-410X.1983.tb03354.x
    1. Lilly JD, Parsons CL: Bladder surface glycosaminoglycans is a human epithelial permeability barrier. Surg Gynecol Obstet. 1990;171(6):493–6.
    1. Parsons CL, Lilly JD, Stein P: Epithelial dysfunction in nonbacterial cystitis (interstitial cystitis). J Urol. 1991;145(4):732–5. 10.1016/S0022-5347(17)38437-9
    1. Chelsky MJ, Rosen SI, Knight LC, et al. : Bladder permeability in interstitial cystitis is similar to that of normal volunteers: direct measurement by transvesical absorption of 99mtechnetium-diethylenetriaminepentaacetic acid. J Urol. 1994;151(2):346–9. 10.1016/S0022-5347(17)34945-5
    1. Parsons CL, Boychuk D, Jones S, et al. : Bladder surface glycosaminoglycans: an epithelial permeability barrier. J Urol. 1990;143(1):139–42. 10.1016/S0022-5347(17)39897-X
    1. Liu HT, Shie JH, Chen SH, et al. : Differences in mast cell infiltration, E-cadherin, and zonula occludens-1 expression between patients with overactive bladder and interstitial cystitis/bladder pain syndrome. Urology. 2012;80(1):225.e13–8. 10.1016/j.urology.2012.01.047
    1. Jhang JF, Ho HC, Jiang YH, et al. : Electron microscopic characteristics of interstitial cystitis/bladder pain syndrome and their association with clinical condition. PLoS One. 2018;13(6):e0198816. 10.1371/journal.pone.0198816

    2. F1000 Recommendation

    1. Sun Y, Keay S, Lehrfeld TJ, et al. : Changes in adenosine triphosphate-stimulated ATP release suggest association between cytokine and purinergic signaling in bladder urothelial cells. Urology. 2009;74(5):1163–8. 10.1016/j.urology.2009.02.066
    1. Dixon JS, Holm-Bentzen M, Gilpin CJ, et al. : Electron microscopic investigation of the bladder urothelium and glycocalyx in patients with interstitial cystitis. J Urol. 1986;135(3):621–5. 10.1016/S0022-5347(17)45763-6
    1. Theoharides TC, Sant GR, el-Mansoury M, et al. : Activation of bladder mast cells in interstitial cystitis: a light and electron microscopic study. J Urol. 1995;153(3 Pt 1):629–36. 10.1016/S0022-5347(01)67669-9
    1. Kim A, Han JY, Ryu CM, et al. : Histopathological characteristics of interstitial cystitis/bladder pain syndrome without Hunner lesion. Histopathology. 2017;71(3):415–24. 10.1111/his.13235

    2. F1000 Recommendation

    1. Richter B, Roslind A, Hesse U, et al. : YKL-40 and mast cells are associated with detrusor fibrosis in patients diagnosed with bladder pain syndrome/interstitial cystitis according to the 2008 criteria of the European Society for the Study of Interstitial Cystitis. Histopathology. 2010;57(3):371–83. 10.1111/j.1365-2559.2010.03640.x
    1. Tyagi P, Tyagi V, Yoshimura N, et al. : Gender-based reciprocal expression of transforming growth factor-beta1 and the inducible nitric oxide synthase in a rat model of cyclophosphamide-induced cystitis. J Inflamm (Lond). 2009;6:23. 10.1186/1476-9255-6-23
    1. Ahn ST, Jeong HG, Park TY, et al. : Differences in Urodynamic Parameters According to the Presence of a Hunner Lesion in Women With Interstitial Cystitis/Bladder Pain Syndrome. Int Neurourol J. 2018;22(Suppl 1):S55–61. 10.5213/inj.1835044.522

    2. F1000 Recommendation

    1. Choi D, Han JY, Shin JH, et al. : Downregulation of WNT11 is associated with bladder tissue fibrosis in patients with interstitial cystitis/bladder pain syndrome without Hunner lesion. Sci Rep. 2018;8(1):9782. 10.1038/s41598-018-28093-7

    2. F1000 Recommendation

    1. Doiron RC, Tolls V, Irvine-Bird K, et al. : Clinical Phenotyping Does Not Differentiate Hunner Lesion Subtype of Interstitial Cystitis/Bladder Pain Syndrome: A Relook at the Role of Cystoscopy. J Urol. 2016;196(4):1136–40. 10.1016/j.juro.2016.04.067

    2. F1000 Recommendation

    1. Hendrix L, Erickson D: Can Urine CXCL-1 And CXCL-10 Levels Serve As Noininvasive Markers For Hunner Lesions In Interstitial Cystitis/Bladder Pain Syndrome? Neurourol Urodyn. 2012;31(2):226
    1. Lee JE, Yi BH, Lee HK, et al. : Correlation of cystoscopically confirmed periureterally located hunner lesion with vesicoureteral reflux: preliminary study in patients with interstitial cystitis. AJR Am J Roentgenol. 2015;204(4):W457–60. 10.2214/AJR.14.13108
    1. Lin CC, Yang AH, Lin AT: Activation of the mTOR dependent signaling pathway underlies ketamine-induced uropathy. Neurourol Urodyn. 2017;36(8):1988–95. 10.1002/nau.23234

    2. F1000 Recommendation

    1. Kim SH, Kim TB, Kim SW, et al. : Urodynamic findings of the painful bladder syndrome/interstitial cystitis: a comparison with idiopathic overactive bladder. J Urol. 2009;181(6):2550–4. 10.1016/j.juro.2009.01.106
    1. Kirkemo A, Peabody M, Diokno AC, et al. : Associations among urodynamic findings and symptoms in women enrolled in the Interstitial Cystitis Data Base (ICDB) Study. Urology. 1997;49(5A Suppl):76–80. 10.1016/S0090-4295(99)80335-5
    1. Osborn DJ, Kaufman MR, Mock S, et al. : Urinary retention rates after intravesical onabotulinumtoxinA injection for idiopathic overactive bladder in clinical practice and predictors of this outcome. Neurourol Urodyn. 2015;34(7):675–8. 10.1002/nau.22642

    2. F1000 Recommendation

    1. SHIPTON EA: HUNNER'S ULCER (CHRONIC INTERSTITIAL CYSTITIS). A MANIFESTATION OF COLLAGEN DISEASE. Br J Urol. 1965;37(4):443–9. 10.1111/j.1464-410X.1965.tb09624.x
    1. Oelke M, Khullar V, Wijkstra H: Review on ultrasound measurement of bladder or detrusor wall thickness in women: techniques, diagnostic utility, and use in clinical trials. World J Urol. 2013;31(5):1093–104. 10.1007/s00345-013-1030-6
    1. Tyagi P, Killinger K, Tyagi V, et al. : Urinary chemokines as noninvasive predictors of ulcerative interstitial cystitis. J Urol. 2012;187(6):2243–8. 10.1016/j.juro.2012.01.034
    1. Homma Y, Ueda T, Tomoe H, et al. : Clinical guidelines for interstitial cystitis and hypersensitive bladder updated in 2015. Int J Urol. 2016;23(7):542–9. 10.1111/iju.13118

    2. F1000 Recommendation

    1. Ueda T, Nakagawa M, Okamura M, et al. : New cystoscopic diagnosis for interstitial cystitis/painful bladder syndrome using narrow-band imaging system. Int J Urol. 2008;15(12):1039–43. 10.1111/j.1442-2042.2008.02179.x

    2. F1000 Recommendation

    1. Khorasani B, Arab AM, Sedighi Gilani MA, et al. : Transabdominal ultrasound measurement of pelvic floor muscle mobility in men with and without chronic prostatitis/chronic pelvic pain syndrome. Urology. 2012;80(3):673–7. 10.1016/j.urology.2012.05.026
    1. Milosević D, Batinic D, Vrljicak K, et al. : Ultrasound distinction between simple recurrent urinary tract infections and a specific bladder wall inflammatory entity called cystitis cystica. Coll Antropol. 2014;38(1):151–4.
    1. Rachaneni S, McCooty S, Middleton LJ, et al. : Bladder ultrasonography for diagnosing detrusor overactivity: test accuracy study and economic evaluation. Health Technol Assess. 2016;20(7):1–150. 10.3310/hta20070
    1. Heritz DM, Thiessen JJ: Tiaprofenic acid: an uncommon cause of cystitis often misdiagnosed as interstitial cystitis. Can J Urol. 1996;3(1):202–5.
    1. Weissleder R, Ntziachristos V: Shedding light onto live molecular targets. Nat Med. 2003;9(1):123–8. 10.1038/nm0103-123
    1. Yhee JY, Kim SA, Koo H, et al. : Optical imaging of cancer-related proteases using near-infrared fluorescence matrix metalloproteinase-sensitive and cathepsin B-sensitive probes. Theranostics. 2012;2(2):179–89. 10.7150/thno.3716
    1. Bremer C, Ntziachristos V, Weissleder R: Optical-based molecular imaging: contrast agents and potential medical applications. Eur Radiol. 2003;13(2):231–43.
    1. Nogawa M, Yuasa T, Kimura S, et al. : Intravesical administration of small interfering RNA targeting PLK-1 successfully prevents the growth of bladder cancer. J Clin Invest. 2005;115(4):978–85. 10.1172/JCI23043
    1. Shadgan B, Nigro M, Macnab A, et al. : Optical diagnosis of lower urinary tract infection: a pilot study in children. J Pediatr Urol. 2015;11(2):74.e1–7. 10.1016/j.jpurol.2014.08.017
    1. Kaneko G, Nishimoto K, Ito Y, et al. : The combination therapy of prednisolone and tacrolimus for severe painful bladder syndrome/interstitial cystitis. Can Urol Assoc J. 2012;6(2):E46–9.
    1. Rabie E, Faeghi F, Izadpanahi MH, et al. : et al. Role of Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Staging of Bladder Cancer. J Clin Diagn Res. 2016;10(4):TC01–5. 10.7860/JCDR/2016/17596.7690

    2. F1000 Recommendation

    1. Tyagi P, Janicki J, Moon CH, et al. : et al. Novel contrast mixture achieves contrast resolution of human bladder wall suitable for T1 mapping: applications in interstitial cystitis and beyond. Int Urol Nephrol. 2018;50(3):401–9. 10.1007/s11255-018-1794-0
    1. Fisher MR, Hricak H, Crooks LE: Urinary bladder MR imaging. Part I. Normal and benign conditions. Radiology. 1985;157(2):467–70. 10.1148/radiology.157.2.4048457
    1. Ma Z, Jorge RN, Mascarenhas T, et al. : Novel approach to segment the inner and outer boundaries of the bladder wall in T2-weighted magnetic resonance images. Ann Biomed Eng. 2011;39(8):2287–97. 10.1007/s10439-011-0324-3
    1. Arum CJ, Kodama Y, Rolim N, et al. : A rat model of intravesical delivery of small interfering RNA for studying urinary carcinoma. World J Urol. 2010;28(4):479–85. 10.1007/s00345-010-0542-6
    1. Takeda K, Kawaguchi T, Shiraishi T, et al. : Normal bladder wall morphology in Gd-DTPA-enhanced clinical MR imaging using an endorectal surface coil and histological assessment of submucosal linear enhancement using [ 14C]Gd-DOTA autoradiography in an animal model. Eur J Radiol. 1998;26(3):290–6. 10.1016/S0720-048X(97)01178-9
    1. Verma S, Rajesh A, Prasad SR, et al. : Urinary bladder cancer: role of MR imaging. Radiographics. 2012;32(2):371–87. 10.1148/rg.322115125
    1. Nguyen HT, Pohar KS, Jia G, et al. : Improving bladder cancer imaging using 3-T functional dynamic contrast-enhanced magnetic resonance imaging. Invest Radiol. 2014;49(6):390–5. 10.1097/RLI.0000000000000022
    1. Hakenberg OW, Linne C, Manseck A, et al. : Bladder wall thickness in normal adults and men with mild lower urinary tract symptoms and benign prostatic enlargement. Neurourol Urodyn. 2000;19(5):585–93. 10.1002/1520-6777(2000)19:5<585::AID-NAU5>;2-U
    1. Alsinnawi M, Torreggiani W, Sheikh M, et al. : Delayed contrast-enhanced MRI to localize Botox after cystoscopic intravesical injection. Int Urol Nephrol. 2015;47(6):893–8. 10.1007/s11255-015-0976-2
    1. Roy C: Tumour pathology of the bladder: the role of MRI. Diagn Interv Imaging. 2012;93(4):297–309. 10.1016/j.diii.2012.01.013
    1. Xiao D, Zhang G, Liu Y, et al. : 3D detection and extraction of bladder tumors via MR virtual cystoscopy. Int J Comput Assist Radiol Surg. 2016;11(1):89–97. 10.1007/s11548-015-1234-x
    1. Maeda H, Kinukawa T, Hattori R, et al. : Detection of muscle layer invasion with submillimeter pixel MR images: staging of bladder carcinoma. Magn Reson Imaging. 1995;13(1):9–19. 10.1016/0730-725X(94)00084-G
    1. Kim B, Semelka RC, Ascher SM, et al. : Bladder tumor staging: comparison of contrast-enhanced CT, T1- and T2-weighted MR imaging, dynamic gadolinium-enhanced imaging, and late gadolinium-enhanced imaging. Radiology. 1994;193(1):239–45. 10.1148/radiology.193.1.8090898
    1. Krhut J, Samal V, Nemec D, et al. : Intradetrusor versus suburothelial onabotulinumtoxinA injections for neurogenic detrusor overactivity: a pilot study. Spinal Cord. 2012;50(12):904–7. 10.1038/sc.2012.76
    1. Narumi Y, Kadota T, Inoue E, et al. : Bladder wall morphology: in vitro MR imaging-histopathologic correlation. Radiology. 1993;187(1):151–5. 10.1148/radiology.187.1.8451403
    1. Teufl F, Dammann F, Wehrmann M: [ In vitro study of morphology of the bladder wall using MR tomography at 1.0 Tesla: correlation with histology]. Rofo. 1997;166(5):406–10. 10.1055/s-2007-1015449
    1. Babcock EE, Brateman L, Weinreb JC, et al. : Edge artifacts in MR images: chemical shift effect. J Comput Assist Tomogr. 1985;9(2):252–7.
    1. Hood MN, Ho VB, Smirniotopoulos JG, et al. : Chemical shift: the artifact and clinical tool revisited. Radiographics. 1999;19(2):357–71. 10.1148/radiographics.19.2.g99mr07357
    1. Lin Q, Liang Z, Duan C, et al. : Motion correction for MR cystography by an image processing approach. IEEE Trans Biomed Eng. 2013;60(9):2401–10. 10.1109/TBME.2013.2257769
    1. Elster AD, Sobol WT, Hinson WH: Pseudolayering of Gd-DTPA in the urinary bladder. Radiology. 1990;174(2):379–81. 10.1148/radiology.174.2.2296649
    1. Rohrer M, Bauer H, Mintorovitch J, et al. : Comparison of magnetic properties of MRI contrast media solutions at different magnetic field strengths. Invest Radiol. 2005;40(11):715–24. 10.1097/01.rli.0000184756.66360.d3
    1. Scattoni V, Da Pozzo LF, Colombo R, et al. : Dynamic gadolinium-enhanced magnetic resonance imaging in staging of superficial bladder cancer. J Urol. 1996;155(5):1594–9. 10.1016/S0022-5347(01)66139-1
    1. Carr DH, Brown J, Bydder GM, et al. : Gadolinium-DTPA as a contrast agent in MRI: initial clinical experience in 20 patients. AJR Am J Roentgenol. 1984;143(2):215–24. 10.2214/ajr.143.2.215
    1. Sparenberg A, Hamm B, Hammerer P, et al. : [The diagnosis of bladder carcinomas by NMR tomography: an improvement with Gd-DTPA?]. Rofo. 1991;155(2):117–22. 10.1055/s-2008-1033231
    1. Lee SK, Chang Y, Park NH, et al. : Magnetic resonance voiding cystography in the diagnosis of vesicoureteral reflux: comparative study with voiding cystourethrography. J Magn Reson Imaging. 2005;21(4):406–14. 10.1002/jmri.20273
    1. Towner RA, Wisniewski AB, Wu DH, et al. : A Feasibility Study to Determine Whether Clinical Contrast Enhanced Magnetic Resonance Imaging can Detect Increased Bladder Permeability in Patients with Interstitial Cystitis. J Urol. 2016;195(3):631–8. 10.1016/j.juro.2015.08.077

    2. F1000 Recommendation

    1. Beyersdorff D, Taupitz M, Giessing M, et al. : [The staging of bladder tumors in MRT: the value of the intravesical application of an iron oxide-containing contrast medium in combination with high-resolution T 2-weighted imaging]. Rofo. 2000;172(6):504–8. 10.1055/s-2000-3751
    1. Tyagi P, Janicki JJ, Hitchens TK, et al. : Novel contrast mixture improves bladder wall contrast for visualizing bladder injury. Am J Physiol Renal Physiol. 2017;313(2):F155–F162. 10.1152/ajprenal.00609.2016
    1. Colaco M, Koslov DS, Keys T, et al. : Correlation of gene expression with bladder capacity in interstitial cystitis/bladder pain syndrome. J Urol. 2014;192(4):1123–9. 10.1016/j.juro.2014.05.047
    1. Nirmal J, Tyagi P, Chancellor MB, et al. : Development of potential orphan drug therapy of intravesical liposomal tacrolimus for hemorrhagic cystitis due to increased local drug exposure. J Urol. 2013;189(4):1553–8. 10.1016/j.juro.2012.10.123
    1. Towner RA, Smith N, Saunders D, et al. : Contrast enhanced magnetic resonance imaging as a diagnostic tool to assess bladder permeability and associated colon cross talk: preclinical studies in a rat model. J Urol. 2015;193(4):1394–400. 10.1016/j.juro.2014.10.120
    1. Chuang YC, Huang TL, Tyagi P, et al. : Urodynamic and Immunohistochemical Evaluation of Intravesical Botulinum Toxin A Delivery Using Low Energy Shock Waves. J Urol. 2016;196(2):599–608. 10.1016/j.juro.2015.12.078
    1. Bloch F: The Principle of Nuclear Induction. Science. 1953;118(3068):425–30. 10.1126/science.118.3068.425
    1. Gowland P, Mansfield P, Bullock P, et al. : Dynamic studies of gadolinium uptake in brain tumors using inversion-recovery echo-planar imaging. Magn Reson Med. 1992;26(2):241–58. 10.1002/mrm.1910260206
    1. Deoni SC: Quantitative relaxometry of the brain. Top Magn Reson Imaging. 2010;21(2):101–13. 10.1097/RMR.0b013e31821e56d8
    1. Fu Y, Tanaka K, Nishimura S: Evaluation of brain edema using magnetic resonance proton relaxation times. Adv Neurol. 1990;52:165–76.
    1. Béné GJ: Water proton relaxation times: main parameters in nuclear magnetic resonance medical diagnosis. Prog Nucl Med. 1984;8:1–14.
    1. Stadler A, Jakob PM, Griswold M, et al. : T 1 mapping of the entire lung parenchyma: Influence of respiratory phase and correlation to lung function test results in patients with diffuse lung disease. Magn Reson Med. 2008;59(1):96–101. 10.1002/mrm.21446
    1. Constantinou CE, Hvistendahl G, Ryhammer A, et al. : Determining the displacement of the pelvic floor and pelvic organs during voluntary contractions using magnetic resonance imaging in younger and older women. BJU Int. 2002;90(4):408–14. 10.1046/j.1464-410X.2002.02907.x
    1. Ebert AK, Rösch WH, Vogt T: Safety and tolerability of adjuvant topical tacrolimus treatment in boys with lichen sclerosus: a prospective phase 2 study. Eur Urol. 2008;54(4):932–7. 10.1016/j.eururo.2008.03.013
    1. Tang ST, Cao GQ, Mao YZ, et al. : Clinical value of pelvic 3-dimensional magnetic resonance image reconstruction in anorectal malformations. J Pediatr Surg. 2009;44(12):2369–74. 10.1016/j.jpedsurg.2009.07.074
    1. Erickson DR, Tomaszewski JE, Kunselman AR, et al. : Urine markers do not predict biopsy findings or presence of bladder ulcers in interstitial cystitis/painful bladder syndrome. J Urol. 2008;179(5):1850–6. 10.1016/j.juro.2008.01.047
    1. Corcoran AT, Yoshimura N, Tyagi V, et al. : Mapping the cytokine profile of painful bladder syndrome/interstitial cystitis in human bladder and urine specimens. World J Urol. 2013;31(1):241–6. 10.1007/s00345-012-0852-y
    1. Peters KM, Jayabalan N, Bui D, et al. : Effect of Sacral Neuromodulation on Outcome Measures and Urine Chemokines in Interstitial Cystitis/Painful Bladder Syndrome Patients. Low Urin Tract Symptoms. 2015;7(2):77–83. 10.1111/luts.12054
    1. Lamb LE, Janicki JJ, Bartolone SN, et al. : Development of an interstitial cystitis risk score for bladder permeability. PLoS One. 2017;12(10):e0185686. 10.1371/journal.pone.0185686
    1. Lowe EM, Anand P, Terenghi G, et al. : Increased nerve growth factor levels in the urinary bladder of women with idiopathic sensory urgency and interstitial cystitis. Br J Urol. 1997;79(4):572–7. 10.1046/j.1464-410X.1997.00097.x
    1. Chen W, Ye DY, Han DJ, et al. : Elevated level of nerve growth factor in the bladder pain syndrome/interstitial cystitis: a meta-analysis. Springerplus. 2016;5(1):1072. 10.1186/s40064-016-2719-y

    2. F1000 Recommendation

    1. Chung CW, Zhang QL, Qiao LY: Endogenous nerve growth factor regulates collagen expression and bladder hypertrophy through Akt and MAPK pathways during cystitis. J Biol Chem. 2010;285(6):4206–12. 10.1074/jbc.M109.040444
    1. Wang J, Chen Y, Di Gu, et al. : Ketamine-induced bladder fibrosis involves epithelial-to-mesenchymal transition mediated by transforming growth factor-β1. Am J Physiol Renal Physiol. 2017;313(4):F961–F972. 10.1152/ajprenal.00686.2016

    2. F1000 Recommendation

    1. Bosch PC: A randomized, double-blind, placebo controlled trial of adalimumab for interstitial cystitis/bladder pain syndrome. J Urol. 2014;191(1):77–82. 10.1016/j.juro.2013.06.038

    2. F1000 Recommendation

    1. Nickel JC, Crossland A, Davis E, et al. : Investigation of a Ca 2+ channel α2δ ligand for the treatment of interstitial cystitis: results of a randomized, double-blind, placebo controlled phase II trial. J Urol. 2012;188(3):817–23. 10.1016/j.juro.2012.05.010

    2. F1000 Recommendation

    1. Nickel JC, Herschorn S, Whitmore KE, et al. : Pentosan polysulfate sodium for treatment of interstitial cystitis/bladder pain syndrome: insights from a randomized, double-blind, placebo controlled study. J Urol. 2015;193(3):857–62. 10.1016/j.juro.2014.09.036
    1. Nickel JC, Hanno P, Kumar K, et al. : Second multicenter, randomized, double-blind, parallel-group evaluation of effectiveness and safety of intravesical sodium chondroitin sulfate compared with inactive vehicle control in subjects with interstitial cystitis/bladder pain syndrome. Urology. 2012;79(6):1220–4. 10.1016/j.urology.2012.01.059
    1. Funaro MG, King AN, Stern JNH, et al. : Endoscopic Injection of Low Dose Triamcinolone: A Simple, Minimally Invasive, and Effective Therapy for Interstitial Cystitis With Hunner Lesions. Urology. 2018;118:25–9. 10.1016/j.urology.2018.03.037

    2. F1000 Recommendation

    1. Ostardo E, Impellizzeri D, Cervigni M, et al. : Adelmidrol + sodium hyaluronate in IC/BPS or conditions associated to chronic urothelial inflammation. A translational study. Pharmacol Res. 2018;134:16–30. 10.1016/j.phrs.2018.05.013

    2. F1000 Recommendation

    1. Lin HC, Lee HS, Chiueh TS, et al. : Histopathological assessment of inflammation and expression of inflammatory markers in patients with ketamine-induced cystitis. Mol Med Rep. 2015;11(4):2421–8. 10.3892/mmr.2014.3110
    1. Metcalfe PD, Wang J, Jiao H, et al. : Bladder outlet obstruction: progression from inflammation to fibrosis. BJU Int. 2010;106(11):1686–94. 10.1111/j.1464-410X.2010.09445.x
    1. Klarskov P, Holm-Bentzen M, Larsen S, et al. : Partial cystectomy for the myogenic decompensated bladder with excessive residual urine. Urodynamics, histology and 2-13 years follow-up. Scand J Urol Nephrol. 1988;22(4):251–6. 10.3109/00365598809180795
    1. Parikh N, Ream JM, Zhang HC, et al. : Performance of simultaneous high temporal resolution quantitative perfusion imaging of bladder tumors and conventional multi-phase urography using a novel free-breathing continuously acquired radial compressed-sensing MRI sequence. Magn Reson Imaging. 2016;34(5):694–8. 10.1016/j.mri.2015.12.033

    2. F1000 Recommendation

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj